"This investigational strategy allows us to collect product performance data" while the full non-administrative new animal drug application submission is in the final stages of review, the company said Wednesday in a statement.

Clearing inspectional observations at the contract manufacturer's facilities "is still the critical path constraint" for approval, the company said.

The test marketing isn't expected to generate significant revenue or profit, the company said.

http://www.mtnewswires.com
Copyright © 2025 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.